Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Buy” by Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been assigned an average rating of “Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $29.86.

A number of research analysts have recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, November 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Jefferies Financial Group decreased their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, HC Wainwright lifted their price objective on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, November 21st.

Kura Oncology Stock Up 0.6 %

NASDAQ KURA opened at $8.73 on Monday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52 week low of $8.42 and a 52 week high of $24.17. The firm has a market capitalization of $678.88 million, a price-to-earnings ratio of -3.70 and a beta of 0.75. The company has a fifty day moving average of $12.48 and a two-hundred day moving average of $17.28.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently modified their holdings of the business. Suvretta Capital Management LLC boosted its stake in shares of Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Armistice Capital LLC boosted its position in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after acquiring an additional 41,535 shares during the period. Franklin Resources Inc. raised its position in shares of Kura Oncology by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after acquiring an additional 23,113 shares in the last quarter. Finally, Candriam S.C.A. raised its position in shares of Kura Oncology by 39.2% in the 2nd quarter. Candriam S.C.A. now owns 906,482 shares of the company’s stock worth $18,664,000 after acquiring an additional 255,065 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.